Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

NB-UVB and PUVA Vitiligo Study

This study has been completed.
Information provided by (Responsible Party):
Iltefat Hamzavi, Henry Ford Health System Identifier:
First received: November 13, 2012
Last updated: February 22, 2017
Last verified: February 2017
To evaluate if the combination of psoralen plus ultraviolet A and narrowband ultraviolet B is more effective than narrowband ultraviolet B alone in the treatment of vitiligo.

Condition Intervention Phase
Other: Phototherapy
Other: Phototherapy and Photochemotherapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo

Resource links provided by NLM:

Further study details as provided by Henry Ford Health System:

Primary Outcome Measures:
  • Determine the quantity of repigmentation [ Time Frame: 6 months ]
    Determination the degree of repigmentation measured by the VASI score (Vitiligo area Scoring Index) after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone.

Secondary Outcome Measures:
  • Determine the quality of repigmentation. [ Time Frame: Study initiation, 3 months and 6 months. ]
    Determination of the color of repigmentation, pattern of repigmentation, and the cessation of spread of vitiligo after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone.

Enrollment: 10
Study Start Date: March 2013
Study Completion Date: May 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: NB-UVB phototherapy
NB-UVB alone
Other: Phototherapy
Experimental: phototherapy and photochemotherapy
Other: Phototherapy and Photochemotherapy


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Vitiligo affecting more than 15% body surface area.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01732965

United States, Michigan
Henry Ford Dermatology
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Principal Investigator: Iltefat Hamzavi, MD Henry Ford Dermatology
  More Information

Responsible Party: Iltefat Hamzavi, Senior Staff Physician, Henry Ford Health System Identifier: NCT01732965     History of Changes
Other Study ID Numbers: HFHS Vitiligo Phototherapy
Study First Received: November 13, 2012
Last Updated: February 22, 2017

Keywords provided by Henry Ford Health System:

Additional relevant MeSH terms:
Pigmentation Disorders
Skin Diseases processed this record on May 24, 2017